Biocom - Life Sciences Association of California
Close
Call
Profile
San Diego  |   Los Angeles  |   Washington, DC  |   Tokyo
cONTENT bLOCK
Left
Left
https://www.biocom.org/servlet/servlet.ImageServer?id=015F0000005wo69IAA&oid=00DA0000000Kz7JMAS  

Venture Day with Novo Ventures - Los Angeles

 
When:
Tuesday, July 11 2017 - Tuesday, July 11 2017
8:00 AM - 5:00 PM

Add to Calendar America/Los_Angeles Venture Day with Novo Ventures - Los Angeles Interested in the latest developments in the venture capital market?  Looking to raise money?  Join us in Los Angeles on Tuesday, July 11th with Novo Ventures (US) for a series of one-on-one meetings with pre-selected companies*. Biocom's track record includes over 125 meetings arranged with 30+ different venture capital firms.  Biocom false MM/DD/YYYY

Where:
Biocom Los Angeles Office
444 South Flower Street, Suite 1780
Los Angeles, California 90071
Registration Deadline:
Monday, June 26 2017
12:00 PM
Register


Biocom Venture Day: Novo Ventures in Los Angeles
 
Interested in the latest developments in the venture capital market?  Looking to raise money?  Join us in Los Angeles on Tuesday, July 11th with Novo Ventures (US) for a series of one-on-one meetings with pre-selected companies. Biocom's track record includes over 125 meetings arranged with 30+ different venture capital firms. 
 
About Novo:
 
Novo Ventures (US) is one of the most active life science venture capital investors in the world. So far, we have invested $1 Billion in more than 120 companies and successfully exited over 30 companies through trade sales and IPOs.
 
We proudly share our positive track record with the talented scientists and inspired entrepreneurs who convert our capital and commercial support into revolutionizing products and technologies. Together, we’re improving the lives of thousands of people around the world
 
Our venture capital goes to promising life science companies – private and public – whose products or research address real medical, scientific or environmental needs. As business investors, we also look for profit and growth potential.
 
Our investment will typically range from USD 5 to 30 million initially per transaction. In addition, we have capacity to make follow-on investments. We may invest at any stage of development – seed capital, venture capital, IPOs and public companies.
 
How to Apply:
 
If you are interested in meeting with the Novo Ventures (US), please send over a one-page non-confidential executive summary for review to Oscar Rodarte at orodarte@biocom.org by June 26th for consideration. 
 
Novo Representative:
 
Eric Shiozaki, PhD, Principal
Eric joined Novo Ventures (US) Inc. in San Francisco, California in 2014. Prior to joining Novo Ventures (US) Inc., Eric was a Director at Apposite Capital where he established the firm’s San Francisco office and managed its secondary direct investment activity in the US. He has also worked for Vitapath Genetics in Business Development and Strategy, and as an Associate at Burrill & Company where he was a member of the firm’s venture capital practice. Before entering venture capital, Eric was a Leukemia & Lymphoma Society Post-Doctoral Fellow at UCLA. While conducting his post-doctoral research, he also spent time in the University’s technology transfer office.
 
Eric received a PhD in Molecular Biology from Princeton University, and a BA in Biophysics from Johns Hopkins University.
 

Planner

Oscar Rodarte
 

Sponsored By: